Sen. Warren’s “War on Pharma”: Rhetorical Blast, But Remarkably Limited Objectives
This article was originally published in RPM Report
Despite her reputation as a populist, anti-corporate crusader, Elizabeth Warren did not focus on Big Pharma in her first years in the Senate. The headlines following a speech by Warren last week suggest that has changed – but the actual legislative proposal looks a lot different than the rhetoric makes it sound.
You may also be interested in...
A Senate hearing on President Obama’s Precision Medicine initiative illustrates how well that theme plays for the biopharma sector. The focus was on the potential for highly effective targeted therapies to help patients—and even lower costs for the system. The price of the drugs themselves was not even raised.
Finance Committee Chair Ron Wyden is promising immediate action to stop the trend of biopharma companies acquiring ex-US firms to reincorporate for tax reasons. The prospects for legislation are limited – but will the debate open up a new angle to attack biopharma pricing in the US?
Sen. Bill Nelson is the primary sponsor of legislation to impose rebates on Medicare Part D. But when he held a hearing on the program in his Aging Committee, something surprising happened: everyone wanted to talk about adherence instead.